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Abstract
Background
Many new clinical prediction rules are derived and validated. But the design and reporting
quality of clinical prediction research has been less than optimal. We aimed to assess
whether design characteristics of validation studies were associated with the overestimation
of clinical prediction rules’ performance. We also aimed to evaluate whether validation stud-
ies clearly reported important methodological characteristics.
Methods
Electronic databases were searched for systematic reviews of clinical prediction rule stud-
ies published between 2006 and 2010. Data were extracted from the eligible validation stud-
ies included in the systematic reviews. A meta-analytic meta-epidemiological approach was
used to assess the influence of design characteristics on predictive performance. From
each validation study, it was assessed whether 7 design and 7 reporting characteristics
were properly described.
Results
A total of 287 validation studies of clinical prediction rule were collected from 15 systematic
reviews (31 meta-analyses). Validation studies using case-control design produced a sum-
mary diagnostic odds ratio (DOR) 2.2 times (95% CI: 1.2–4.3) larger than validation studies
using cohort design and unclear design. When differential verification was used, the sum-
mary DOR was overestimated by twofold (95% CI: 1.2 -3.1) compared to complete, partial
and unclear verification. The summary RDOR of validation studies with inadequate sample
size was 1.9 (95% CI: 1.2 -3.1) compared to studies with adequate sample size. Study site,
reliability, and clinical prediction rule was adequately described in 10.1%, 9.4%, and 7.0%
of validation studies respectively.
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Conclusion
Validation studies with design shortcomings may overestimate the performance of clinical
prediction rules. The quality of reporting among studies validating clinical prediction rules
needs to be improved.
Introduction
Clinical prediction rules help clinicians address uncertainties surrounding the diagnosis, prog-
nosis or response to treatment using information from individual patient’s history, physical
examination and test results [1–3]. Contrary to the traditional approach where intuition is typi-
cally used to handle clinical uncertainties, clinical prediction rules enable clinicians to explicitly
integrate information from individual patients and estimate the probability of an outcome.
Once a clinical prediction rule is constructed in a derivation study by combining variables
predictive of an outcome, the reproducibility and generalizability of the clinical prediction rule
should be evaluated in validation studies [4–8]. A clinical prediction rule that performed well
in a derivation may not fare so well when it is applied to different populations or settings [6, 9–
11]. Therefore, only clinical prediction rules that have proven performance through external
validations should be trusted and considered for application in clinical practice [5, 12].
There have been several methodological standards proposed over the past three decades
that considered design and reporting characteristics of studies deriving, validating as well as
assessing the impact of clinical prediction rules [1–3, 5, 8, 12, 13]. Despite the available meth-
odological standards, overall methodological qualities of clinical prediction rule research
described in previous reports have been far from optimal [1, 2, 14–17]. However, the findings
of these reports were largely based on the evaluation of derivation studies while including a
limited number of validation studies. Recently, a systematic review of multivariable prediction
models collected from core clinical journals showed that important methodological character-
istics are poorly described in validation studies [18].
There is a growing body of empirical evidence showing that the design and conduct of a study
can influence the results. For example, a number of meta-epidemiological studies which examined
clinical trials included in meta-analyses have shown that failure to ensure proper random sequence
generation, allocation concealment or blinding can lead to the overestimation of treatment effects
[19–22]. In diagnostic test accuracy studies, it has been suggested that the use of less than optimal
study design characteristics such as retrospective data collection, nonconsecutive subject selection
or case-control design may lead to overestimated test accuracy [23, 24]. For validation studies of
clinical prediction rules, the potential implications of employing design characteristics that are not
compatible with currently available methodological standards are yet to be determined.
Our primary objective was to evaluate whether validation studies conducted using design
characteristics that are inconsistent with methodological standards are associated with the
overestimation of predictive performance. We also aimed to estimate the proportion of pub-
lished validation studies that clearly reported important methodological characteristics so that
the readers could assess the validity.
Materials and Methods
Reporting and design characteristics of studies validating clinical
prediction rule
The methodological standards for clinical prediction rules [1–3, 13] as well as quality assess-
ment tools and a reporting guideline for diagnostic test accuracy studies [25–27] were reviewed
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to identify reporting and design characteristics of studies validating clinical prediction rules.
Definitions of 7 reporting characteristics and 7 design characteristics examined in our study
are outlined in Table 1.
Simulations have shown that validation studies with less than 100 patients with and without
an outcome may not identify the invalidity of a regression model [11, 28]. Case-control design,
nonconsecutive enrollment, and retrospective data collection may lead to a biased selection of
patients [29, 30]. Case-control design was associated with the overestimation of diagnostic test
accuracy in a meta-epidemiological study [23]. Case-control design may be obvious when
patients with clinical suspicion and healthy subjects without clinical suspicion are recruited
separately [31]. However, it may be indistinct when an outcome is determined before the pre-
diction is assessed in a “reversed-flow" design [31]. Knowing the result of the prediction may
influence the assessment of an outcome and knowing the outcome of a patient may influence
estimating the prediction [1–3, 13] although blinding did not significantly influence diagnostic
test accuracy in meta-epidemiological studies [23, 24]. Partial or differential verification of pre-
dictions may lead to verification bias. Differential verification was associated with the overesti-
mation of diagnostic accuracy [23, 24]. Even though validation type is not a methodological
standard, this feature was included in our meta-epidemiological analysis since the type of vali-
dation is likely to influence the performance of a clinical prediction rule in validation.
Table 1. Definitions of (a) reporting and (b) design characteristics.
(a) Reporting characteristic Deﬁnition
Population Age, sex and important clinical characteristics are described
Study site Geographic location, institution type and setting, and how patients were referred are described
Prediction rule Clear and detailed descriptions of predictor variables and prediction rule are provided with a description of process to
ensure accurate assessment of rule such as training
Reliability Intra-observer or inter-observer reliability of prediction rule is described
Outcome Clear and detailed deﬁnition of outcome is provided
Results Estimates of predictive performance are presented with conﬁdence intervals
Follow up Clearly describes what happened to all enrolled patients
(b) Design characteristic Level Deﬁnition
Sample size Adequate At least 100 patients with outcome and 100 patients without outcome
Inadequate Less than 100 patients with outcome or 100 patients without outcome
Patient selection Consecutive All consecutive patients meeting inclusion criteria are selected
Nonconsecutive Selection methods other than consecutive selection were used
Disease spectrum Cohort Prediction is ascertained before outcome is determined
Case-control Prediction is ascertained after outcome is determined
Validation type Broad Validation in different settings, with different patients and by different clinicians
Narrow Validation in similar settings, with similar patients or by similar clinicians
Internal Validation using methods such as split-sample validation, cross-validation or bootstrap
Assessment Blind Assessment of prediction without the knowledge of outcome and assessment of outcome without the
knowledge of prediction
Non-blind Assessment of prediction with the knowledge of outcome or assessment of outcome with the
knowledge of prediction
Veriﬁcation Complete All predictions are veriﬁed using the same reference standard
Partial Only a subset of predictions are veriﬁed
Differential A subset of predictions are veriﬁed using different reference standard
Data collection Prospective Data collection for validation study is planned before prediction and outcome are assessed
Retrospective Prediction and outcome are assessed before data collection for validation starts
doi:10.1371/journal.pone.0145779.t001
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Selection of systematic reviews and validation studies
Medline, EMBASE, the Cochrane library and the Medion database (www.mediondatabase.nl)
were searched for systematic reviews of clinical prediction rule studies. Searches were limited
to the systematic reviews published between 2006 and 2010. No language restriction was
applied. All electronic data base searches were conducted on 11 November 2011.
The search strategies for electronic databases were constructed by combining terms from
validated filters for clinical prediction rule study and systematic review [32–35]. Search strate-
gies for Medline (OvidSP™, 1946 to 2011), EMBASE (OvidSP™, 1974 to 2011), the Cochrane
library, and the Medion database (www.mediondatabase.nl) are presented in S1 Fig.
Selection of studies was carried out in two steps. First, eligible systematic reviews of clinical
prediction rule studies were identified from the results of the electronic database search. Then,
eligible validation studies of clinical prediction rule included in these systematic reviews were
selected for data extraction.
A systematic review of clinical prediction rule studies was eligible if:
1. it examined a clinical prediction rule which is defined for this study as a tool that produces a
probability of an outcome to help clinicians with the diagnosis, prognosis or treatment deci-
sion by combining three or more predictor variables from patient’s history, physical exami-
nation or test results,
2. it meta-analyzed the results of clinical prediction rule studies,
3. at least one meta-analysis pooled the results of four or more validation studies of a same
clinical prediction rule,
4. a diagnostic 2 by 2 table could be constructed from four or more validation studies, and
5. the primary studies were not selected or excluded based on any of the seven study design
characteristics examined in this study.
Once a systematic review of clinical prediction rule studies was determined eligible, full text
articles of all clinical prediction rule studies included in the systematic review were reviewed. A
clinical prediction rule study was included if:
1. it was a validation study of clinical prediction rule in which the generalizability of an existing clin-
ical prediction rule was assessed by comparing its prediction with a pre-specified outcome, and
2. the information from the study allowed for the construction of a diagnostic 2 by 2 table.
Data extraction and analysis
From each eligible validation study, a diagnostic 2 by 2 table was constructed and the reporting
and design characteristics were recorded. A systematic review may contain multiple meta-anal-
yses that pooled the results of clinical prediction rule studies using various thresholds. There-
fore, the following strategy was used to identify an optimal threshold for data extraction from a
validation study. The strategy was aimed at including the maximum number of validation stud-
ies while minimizing heterogeneity of data due to threshold effects and preventing a validation
study from being included in multiple analyses.
1. when the results of clinical prediction rule studies were meta-analyzed at a single threshold,
this threshold was used for our data analysis.
2. when the results of clinical prediction rule studies were meta-analyzed at multiple common
thresholds, the threshold that would maximize the number of eligible validation studies was
chosen for data extraction.
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3. when the results of clinical prediction rule studies with various thresholds were meta-ana-
lyzed and the thresholds of validation studies used in meta-analysis are known, each thresh-
old that was chosen by authors of the systematic review to conduct meta-analysis was used.
Meta-epidemiological studies evaluate biases related to study characteristics by collecting
and analyzing many meta-analyses. A multilevel logistic regression is commonly used in meta-
epidemiological studies but it may underestimate standard errors and is mathematically com-
plex since an indicator variable is required for each primary study and each meta-analysis [36].
We used a “meta-meta-analytic approach” to examine the influence of design characteristics
on the performance of clinical prediction rule which involves two steps, a meta-regression and
a meta-analysis of regression coefficients [36].
Firstly, a multivariable meta-regression was conducted in each meta-analysis for seven
design characteristics using Meta-Disc [37] which carries out a meta-regression by adding
covariates to the Moses-Littenberg model [38, 39]. The output of the meta-regression in Meta-
Disc includes a coefficient which is the natural logarithm of relative diagnostic odds ratio
(RDOR) and a standard error of coefficient. Performance of a clinical prediction rule in a vali-
dation study can be presented with a diagnostic odds ratio (DOR). A relative diagnostic odds
ratio (RDOR) is a ratio of the DOR of a prediction rule with a certain study characteristic (e.g.
case-control design) and the DOR of a prediction rule without the study characteristic. In
other words, a RDOR represents the influence of a study characteristic on the performance of
clinical prediction rules. As a significant amount of heterogeneity was expected between valida-
tion studies of a clinical prediction rule, meta-regressions were conducted under the random-
effects assumption.
Secondly, the results of meta-regressions were meta-analyzed using Stata 12 [40]. The
regression coefficients computed in the first step were meta-analyzed using the DerSimonian
and Laird option in Metaan command [41]. Then, the summary RDORs were obtained from
the antilogarithms of the meta-analyses results. A significant heterogeneity was assumed to be
present between the results of meta-regressions and random-effects meta-analyses were
conducted.
The search, selection, data extraction were completed by one of the authors (J.B.). Two clini-
cal epidemiologists (J.E. and I.U.) independently extracted a second set of data from a random
sample of validation studies included in data analysis for comparison. The agreements on the
assessments of six design characteristics were evaluated using Cohen’s kappa.
Results
Selection of material and description of sample
The selection processes for eligible systematic reviews and validation studies are illustrated in
S2 Fig. From 46848 references found in the electronic database search, 15 eligible systematic
reviews consisting of 31 meta-analyses were identified [42–56]. There were 287 validation stud-
ies from 229 clinical prediction rule articles included in these meta-analyses that met the inclu-
sion criteria.
The description of the 15 systematic reviews included in the study are outlined in S1 Table.
Although the systematic reviews of clinical prediction rule published between 2006 and 2010
were searched, 13 of 15 systematic reviews in the sample were from either year 2009 or 2010.
Eleven systematic reviews evaluated diagnostic prediction rules whereas four systematic
reviews examined prognostic prediction rules. Meta-analyses generally contained a small num-
ber of validation studies. Twenty one meta-analyses (67.7%) included 10 or less validation
studies. Only one (3.2%) meta-analysis was conducted with more than twenty validation
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studies. Fifteen meta-analyses evaluated objective outcomes such as the presence of ovarian
malignancy [46] whereas sixteen meta-analyses evaluated subjective outcomes such as the diag-
nosis of postpartum depression [47].
Two hundred and seventy eight validation studies (96.9%) were written in English. There
were only 12 validation studies conducted before 1991. The number of validation studies
increased to 110 between 1991 and 2000 and to 165 between 2001 and 2010.
Quality of reporting in validation studies of clinical prediction rule
As presented in Fig 1, validation studies providing insufficient descriptions of reporting charac-
teristics were common. Study site, reliability, and clinical prediction rule were inadequately
reported in the majority of validation studies. For reporting of study site, 118 (41.1%), 113
(39.3%) and 241 (84.0%) validation studies provided insufficient descriptions of location, insti-
tution type and referral to study site respectively. For reporting of clinical prediction rule, the
processes to ensure an accurate application of prediction rule such as training were described
in 20 (7.0%) validation studies. Predictive performance was reported with confidence interval
in 84 (36.7%) validation studies. Although 145 (50.5%) validation studies provided information
on the follow up of patients, flow diagram was used only in 23 (8.0%) validation studies.
There were 66 (23%) validation studies meeting 0 or 1 reporting characteristic and 147
(51.2%) validation studies satisfying 2 or 3 reporting characteristics. Although only 74 (25.8%)
validation studies met 4 or more reporting characteristics, the proportion of validation studies
satisfying 4 or more reporting characteristics increased from 8.9% between 1991 and 1995, to
27.7% between 1996 and 2000, to 25.9% between 2001 and 2005, and to 42.1% between 2006
and 2010 as seen in Fig 2(A).
Fig 1. Quality of reporting. Proportion of validation studies with adequate and inadequate description of
reporting characteristics.
doi:10.1371/journal.pone.0145779.g001
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Influence of design characteristics on predictive performance of clinical
prediction rule
Design shortcomings and insufficient descriptions of design characteristics were prevalent
among validation studies of clinical prediction rule as presented in S2 Table.
There were 53 (18.5%) validation studies meeting 0 or 1 design characteristic and 161
(56.1%) validation studies satisfying 2 or 3 design characteristics. There were 73 (25.4%) valida-
tion studies conducted while satisfying 4 or more design characteristics. The proportion of vali-
dation studies satisfying 4 or more reporting characteristics did not improve over time as seen
in Fig 2(B). Between 2006 and 2010, there were 15 (26.3%) validation studies that satisfied 4 or
more design characteristics.
Fisher’s exact test showed that patient selection (p = 0.028), disease spectrum (p = 0.008),
and data collection (p = 0.00) significantly varied between validation studies of diagnostic and
prognostic prediction rules. For example, nonconsecutive selection was more common among
diagnostic rules (17.5%) compared to prognostic rules (4.8%). Case-control design was also
more prevalent among diagnostic rules (21.6%) compared to prognostic rules (4.8%). On the
other hand, retrospective data collection was more frequently found in prognostic rules (50%)
than diagnostic rules (16.7%). Although there was no significant overall variation in verifica-
tion between diagnostic and prognostic rules, all studies using differential verification validated
diagnostic prediction rules.
Validation studies using inadequate sample size and differential verification were associated
with the overestimation of predictive performance in univariable analysis as presented in S2
Table. In order to construct a multivariable model, some of the levels for design characteristics
were collapsed according to the summary RDORs from the univariable analysis. Consecutive
selection and unclear patient selection were collapsed and compared with non-consecutive
selection. Case-control design was compared after cohort design and unclear spectrum were
combined. Narrow validation was compared with a combined category of broad validation and
unclear validation type. Differential verification was compared with a combined category of
complete, partial, and unclear verification. Lastly, prospective and retrospective data collection
were collapsed and compared with unclear data collection according to the summary RDORs
from the univariable model. Blind assessment of prediction and outcome was not clearly
Fig 2. Evolution of methodological quality over time. Proportion of validation studies satisfying (a) reporting characteristics and (b) design characteristics
recommended in methodological standards.
doi:10.1371/journal.pone.0145779.g002
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reported in 207 (72.1%) of the validation studies. Therefore, this feature was excluded in the
multivariable model.
The results of the multivariable analysis are presented in Fig 3. Validation studies using
case-control design produced the largest summary RDOR of 2.2 (95% CI: 1.2–4.3) compared
to the validation studies with cohort design and unclear disease spectrum when controlled for
the influence of other design characteristics in the multivariable model. The summary RDOR
for differential verification compared to complete, partial, and unclear verification was 2.0
(95% CI: 1.2–3.1) indicating that validation studies using differential verification are likely to
overestimate DOR by twofold. Validation studies conducted with inadequate sample size pro-
duced a summary RDOR of 1.9 (95% CI: 1.2–3.1).
The summary RDOR of narrow validation was 1.8 with a large 95% confidence interval of
0.8 to 4.4. When an outlier meta-analysis that produced a large coefficient in meta-regression
was excluded, the summary RDOR of narrow validation was reduced to 1.3 with a less wide
95% confidence interval of 0.6 to 2.8. The outlier meta-analysis summarized performance of
HADS, the Hospital Anxiety and Depression Scale, in palliative care setting [55].
Validation studies with unclear data collection methods produced a summary RDOR that
was 20% larger than the summary RDOR of validation studies that clearly used prospective or
retrospective data collection. However, the 95% confidence interval of the summary RDOR for
validation studies with unclear data collection was 0.3 to 5.0. The wide 95% confidence interval
may have been caused by the small number of heterogenous meta-analyses (I 2 = 65.1%) con-
tributing to the estimation of the summary RDOR in this category.
Random-effects assumption between the results of meta-regressions was tested in sensitivity
analysis. The conclusions in univariable and multivariable models were unaffected under fixed
effect assumption. From 78 randomly selected validation studies, a second set of data were
extracted independently for comparison. Cohen’s kappa was 0.64, 0.39, 0.05, 0.24, 0.00 and 0.26
for sample size, patient selection, spectrum, validation type, verification and data collection.
Fig 3. Influence of design characteristics on the performance of clinical prediction rule in multivariable analysis.
doi:10.1371/journal.pone.0145779.g003
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Discussion
In this meta-epidemiological study, we investigated whether validation studies with less than
optimal design characteristics are associated with the overestimation of predictive perfor-
mance. We also evaluated whether studies validating clinical prediction rules are published
while providing sufficient descriptions of design and reporting characteristics recommended in
methodological standards.
Our results showed that many validation studies are conducted using design characteristics
inconsistent with recommendations from methodological standards. The results also demon-
strated that validation studies with design shortcomings overestimate the predictive perfor-
mance. Among the design characteristics examined, case-control design was associated with
the largest overestimation of predictive performance. This is consistent with the previous
observation by Lijmer et al. [23] that using case-control design in diagnostic test accuracy stud-
ies lead to the largest overestimation of test accuracy. Case-control design was uncommon in
diagnostic test accuracy studies according to the previous reports by Lijmer et al. [23] and
Rutjes et al. [24] where it was used in 2.3% and 8.6% of their studies respectively. It is concern-
ing since case-control design was used in 19.2% of validation studies of clinical prediction rule
in our study. We used the definition of case-control design by Rutjes et al. [31] which included
a "reversed-flow" design where an outcome is determined before the prediction is assessed. The
use of this definition may have lead to the detection of validation studies using less obvious
case-control design. Furthermore, the higher prevalence of case-control design in our sample
may reflect lower overall methodological quality of validation studies compared to diagnostic
test accuracy studies. Readers should pay close attention to detect case-control design which is
relatively common among validation studies of clinical prediction rule and should use caution
interpreting the results if a clinical prediction rule was validated using case-control design.
Although differential verification was less commonly observed compared to case-control
design in the present study sample, it was also associated with substantial overestimation of
predictive performance. This finding is similar to the previous observation by Lijmer et al. [23]
in diagnostic test accuracy studies. Clinicians evaluating the performance of clinical prediction
rule should be careful with the results of a validation study when subsets of predictions were
verified with different reference standards.
The results showed that 87.1% of validation studies used less than sufficient number of sub-
jects for validation of logistic regression model. These studies with inadequate sample size were
associated with the overestimation of predictive performance by almost twofold. This is a con-
firmation of findings from simulations by Vergouwe et al. [28] and Steyerberg [11] that at least
100 subjects with the outcome and 100 subjects without the outcome were needed to detect a
modest invalidity in logistic regression models.
Although it is logical to presume that clinical prediction rules would perform less well in
broad validation, our study failed to observe an association between the validation type and the
performance of clinical prediction rule when controlled for the influence of other design char-
acteristics. It was common to find that all or nearly all studies included in a meta-analysis were
classified as the same validation type (e.g. narrow validation) and a regression coefficient could
not be generated for this feature in many meta-regressions. Meta-analyzing a small number of
regression coefficients may have resulted in the imprecise estimation of a summary RDOR.
Nonconsecutive selection does not appear to influence the performance of clinical prediction
rule in validation studies. This finding is similar to previous observations by Lijmer et al. [23]
and Stengel et al. [57].
Potential clinical implication of findings from the present study is discussed in the
following example. According to one of the articles in the present study sample that validated
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classification criteria for rheumatoid arthritis in an outpatient setting, the sensitivity and speci-
ficity of 1987 American College of Rheumatology (ACR) criteria were both 90% [58]. However,
the DOR of 81 calculated from the sensitivity and specificity may have been overestimated by
4.2 fold since this study was conducted using inadequate sample size as well as case-control
design. This means that if adequate sample size and cohort design were used, the DOR would
have been about 19 with corresponding sensitivity and specificity of 81%.
Fig 4 illustrates potential clinical consequences of applying biased results using a hypotheti-
cal patient with 10% risk of rheumatoid arthritis. If the presence of rheumatoid arthritis is pre-
dicted with 1987 ACR criteria using the sensitivity and specificity of 90% as presented by the
authors [58], the probability of rheumatoid arthritis in this patient would be 50%. On the other
hand, applying the sensitivity and specificity of 81% from a hypothetical unbiased study, the
probability of rheumatoid arthritis in this patient would be only 32%. In summary, applying
the potentially biased results from validation studies with design shortcomings may produce
overly confident clinical predictions. Consequently, unnecessary or potentially harmful therapy
may be given to patients and life saving intervention may be withheld.
Fig 4. Fagan nomogram. Applying the sensitivity and specificity of (a) 90% as presented in the validation study [58] and (b) 81% from an unbiased study to a
patient with 10% probability of rheumatoid arthritis.
doi:10.1371/journal.pone.0145779.g004
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The reporting quality of validation studies included in the present study sample was poor.
Inadequate descriptions of study site, reliability, and clinical prediction rule were highly preva-
lent. The results presented with confidence intervals and follow-up of study participants using
flow diagram were found only in a small number of validation studies which is consistent with
the findings from a recent systematic review [18]. Many validation studies did not describe
whether blind assessments of clinical prediction rule and outcome were carried out.
For the findings of validation studies to be trusted and to be safely applied to clinical prac-
tice, the design, conduct and analysis of validation study must be clearly and accurately
described. Unfortunately, the existing evidence including our study indicates key information
is often missing or not clearly reported in validation studies. Collins et al. [59] published the
TRIPOD (Transparent Reporting of multivariable prediction model for Individual Prognosis
Or Diagnosis) statement which is a 22-item checklist for reporting derivation and validation of
clinical prediction models. Although many methodological features evaluated in our study are
included in the TRIPOD statement, there are items that are not examined in our study. Future
research should examine the impact of TRIPOD statement in reporting of prediction rule
studies.
The main limitation of this study is that only data from a limited number of validation stud-
ies could be independently assessed by other reviewers. Restraints in time and funding prohib-
ited complete independent verification of data. Furthermore, there were considerable
disagreements in interpretations of design characteristics between reviewers. Unfortunately,
clear resolution of the disagreement was impossible for most cases due to ambiguity in descrip-
tion of these design characteristics in validation studies. Secondly, the small number of valida-
tion studies included in meta-analyses of clinical prediction rule studies prohibited
incorporating more covariates in the multivariable model. As meta-analyses of clinical predic-
tion rule studies become more readily available, sampling the meta-analyses with a greater
number of validation studies may allow for the examination of additional covariates that influ-
ence the predictive performance. Finally, a meta-meta-analytic approach used in our study
does not formally account for the clustering of DORs among clinical domains or clinical pre-
diction rules compared to a multilevel regression modeling approach. Although this method
performed well in a meta-epidemiological study of clinical trials [36], its robustness is not
known in handling heterogenous validation studies of prediction rules and meta-analyses of
validation studies.
In conclusion, our study demonstrated that many validation studies of clinical prediction
rule are published without complying with reporting and design characteristics recommended
in the methodological standards. The results of validation studies should be interpreted with
caution if design shortcomings such as use of case-control design, differential verification or
inadequate sample size are present as the predictive performance may have been overesti-
mated. Conscious efforts are needed to improve the quality of design, conduct and reporting of
validation studies.
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